Good evening :)
$
₹
Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals Ltd

KNSA

NASDAQ
Asset Logo

Kiniksa Pharmaceuticals Ltd

KNSA

NASDAQ
$77.172.72% (-2.15)
$
₹
$77.172.72% (-2.15)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Mid Cap

With a market cap of $6.1B the stock is ranked 1314

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

76.09
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

8.96
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$1.02
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

9.59%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 6 analysts' reports

Buy
6 analysts
Hold
0 analyst
Sell
0 analyst

Analysts expect a +26.88% price upside over the next year

Current Price$77.17
Target Price$98

Company Profile

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
74.15
74.15
1Y Return
19.79%
19.79%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
23.30
23.30
1Y Return
38.66%
38.66%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
32.8%
32.8%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.94
29.94
1Y Return
31.31%
31.31%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
19.15
19.15
1Y Return
31.25%
31.25%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Kiniksa Pharmaceuticals Ltd 76.098.96-
AbbVie Inc74.1550.450.53
Amgen Inc23.3017.372.26

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

180.8
18.4
202.1
14.1
214.2
22.5
243.6
25.4
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue79.85108.63112.21122.53137.78156.79180.85202.12214.26243.6
Net Income-17.70-3.90-12.69-8.888.5317.8318.4314.1922.5925.43
Net Profit Margin-22.16%-3.59%-11.31%-7.25%6.19%11.37%10.19%7.02%10.54%10.44%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Kiniksa Pharmaceuticals Ltd (KNSA) share price today is $77.17 as of September 19, 2026 at 1:30 AM IST. The stock touched a day high of $79.39 and a day low of $77.02.

  2. Kiniksa Pharmaceuticals Ltd stock trades on NASDAQ under the ticker symbol KNSA.

  3. Kiniksa Pharmaceuticals Ltd's market capitalization is $6.05B as of September 19, 2026 at 1:30 AM IST.

  4. Kiniksa Pharmaceuticals Ltd's price-to-earnings (P/E) ratio is 76.09 as of September 18, 2026.

  5. Kiniksa Pharmaceuticals Ltd's price-to-book (P/B) ratio is 8.96 as of September 18, 2026.

  6. Yes, You can buy Kiniksa Pharmaceuticals Ltd shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Kiniksa Pharmaceuticals Ltd shares in three steps: 1. Search Kiniksa Pharmaceuticals Ltd on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Kiniksa Pharmaceuticals Ltd trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Kiniksa Pharmaceuticals Ltd (KNSA) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.1295 shares at the current price of $77.17.

Loading...